We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+17.45%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$587M
AUM Growth
+$91.8M
Cap. Flow
+$8.65M
Cap. Flow %
1.47%
Top 10 Hldgs %
69.79%
Holding
31
New
4
Increased
12
Reduced
11
Closed
1

Top Buys

Rank Stock Value
1
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$45.1M
2
BPMC
Blueprint Medicines
BPMC
+$13M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.2M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$10.1M
5
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$9.74M

Top Sells

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$22.4M
2
LOXO
Loxo Oncology, Inc
LOXO
+$22M
3
ARRY
Array Biopharma Inc
ARRY
+$13.7M
4
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$7.88M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 65.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$60M 10.23%
2,278,459
+575,805
+34% +$13M
CCXI
2
DELISTED
ChemoCentryx, Inc.
CCXI
$54.1M 9.22%
6,677,722
-895,771
-12% -$6.34M
CTIC
3
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$53.9M 9.18%
4,379,561
+3,379,561
+338% +$45.1M
CNCE
4
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$42.3M 7.22%
2,232,014
-23,154
-1% -$503K
CASC
5
DELISTED
Cascadian Therapeutics, Inc.
CASC
$41.7M 7.11%
3,133,228
+406,472
+15% +$7M
VTAE
6
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$37.3M 6.36%
2,061,325
-314,608
-13% -$4.33M
IRWD icon
7
Ironwood Pharmaceuticals
IRWD
$614M
$34M 5.8%
3,505,554
-2,314,447
-40% -$22.4M
CYTK icon
8
Cytokinetics
CYTK
$10.9B
$30.6M 5.21%
2,920,628
+813,639
+39% +$7.98M
ARRY
9
DELISTED
Array Biopharma Inc
ARRY
$28.2M 4.81%
6,682,711
-2,997,919
-31% -$13.7M
FWP
10
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$27.4M 4.67%
205,898
+60,709
+42% +$9.74M
OMED
11
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$22.3M 3.81%
991,433
-384,680
-28% -$7.88M
LOXO
12
DELISTED
Loxo Oncology, Inc
LOXO
$20.2M 3.45%
711,067
-820,041
-54% -$22M
ARQL
13
DELISTED
Arqule Inc
ARQL
$14.8M 2.52%
6,809,843
+243,695
+4% +$547K
QLTI
14
DELISTED
QLT Inc
QLTI
$14.3M 2.43%
5,364,385
+1,626,939
+44% +$4.58M
CTMX icon
15
CytomX Therapeutics
CTMX
$714M
$12.7M 2.17%
+608,848
New +$9.63M
TBRA
16
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$12.6M 2.15%
1,253,401
+78,168
+7% +$812K
FPRX
17
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$12.4M 2.12%
+300,000
New +$10.1M
ALPN
18
DELISTED
Alpine Immune Sciences Inc
ALPN
$9.25M 1.58%
+298,753
New +$10.2M
XENE icon
19
Xenon Pharmaceuticals
XENE
$6.2B
$9.05M 1.54%
1,125,572
+90,000
+9% +$771K
ONCT
20
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$7.81M 1.33%
7,974
+279
+4% +$369K
VIRX
21
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.29M 0.73%
22,749
+10,844
+91% +$2.03M
FLNA
22
Filana Therapeutics
FLNA
$46.4M
$3.24M 0.55%
264,622
+131,942
+99% +$1.75M
GYRE icon
23
Gyre Therapeutics
GYRE
$648M
$3.04M 0.52%
8,631
-443
-5% -$174K
GBIM
24
DELISTED
GLOBEIMMUNE INC COM STK (DE)
GBIM
$2.54M 0.43%
657,653
-20,747
-3% -$66.4K
SVRA icon
25
Savara
SVRA
$1.14B
$1.55M 0.26%
52,814
-20,101
-28% -$625K
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2015 Portfolio in Review

As of Q4 2015, BVF Inc held 31 positions worth $587M, up 19% from $495M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

BVF Inc's Q4 2015 filing shows 4 new, 12 increased, 11 reduced and 1 closed positions. Its largest new stake was Alpine Immune Sciences Inc: 298,753 shares worth $9.25M. The largest sale was Ironwood Pharmaceuticals, an estimated $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 62% a quarter earlier.

  • BVF Inc's largest Q4 2015 buy was Alpine Immune Sciences Inc: 298,753 shares worth $9.25M.
  • BVF Inc added most to CTI BioPharma Corp. (DE) Common Stock in Q4 2015, an estimated $45.1M increase.
  • BVF Inc's biggest Q4 2015 reduction was Ironwood Pharmaceuticals, cutting an estimated $22.4M.
  • BVF Inc fully exited Aptose Biosciences, Inc. in Q4 2015, selling an estimated $179K.
  • BVF Inc's ten largest holdings make up 70% of its $587M portfolio in Q4 2015.
  • BVF Inc opened 4 new positions and closed 1 in Q4 2015.
  • BVF Inc's portfolio value rose 19% quarter-over-quarter to $587M.

Based on BVF Inc's 13F filing for Q4 2015, filed 16 Feb 2016.